Did you mean aromatase inhibitor?
Displaying drugs 1 - 25 of 2428 in total
Exemestane
Exemestane is an oral steroidal aromatase inhibitor used in the adjuvant treatment of hormonally-responsive (also called hormone-receptor-positive, estrogen-responsive) breast cancer in postmenopausal women. It irreversibly binds to the active site of the enzyme resulting in permanent inhibition.
Approved
Investigational
Matched Description: … Exemestane is an oral steroidal aromatase inhibitor used in the adjuvant treatment of hormonally-responsive …
Matched Categories: … Aromatase Inhibitors ... Enzyme Inhibitors ... Steroid Synthesis Inhibitors …
Matched Categories: … Aromatase Inhibitors ... Enzyme Inhibitors ... Steroid Synthesis Inhibitors …
Letrozole
Letrozole, or CGS 20267, is an oral non-steroidal type II aromatase inhibitor first described in the literature in 1990.[A190543,A1559,L11623,L11626] It is a third generation aromatase inhibitor like exemestane and anastrozole, meaning it does not significantly affect cortisol, aldosterone, and thyroxine. Letrozole was granted FDA approval on 25 July 1997.
Approved
Investigational
Matched Description: … Letrozole, or CGS 20267, is an oral non-steroidal type II aromatase inhibitor first described in the ... [A190543,A1559,L11623,L11626] It is a third generation aromatase inhibitor like [exemestane] and [anastrozole …
Matched Categories: … Aromatase Inhibitors ... Enzyme Inhibitors ... Steroid Synthesis Inhibitors ... Cytochrome P-450 CYP2A6 Inhibitors ... Cytochrome P-450 CYP2C19 Inhibitors …
Matched Categories: … Aromatase Inhibitors ... Enzyme Inhibitors ... Steroid Synthesis Inhibitors ... Cytochrome P-450 CYP2A6 Inhibitors ... Cytochrome P-450 CYP2C19 Inhibitors …
Formestane
Formestane was the first selective, type I, steroidal aromatase inhibitor used in the treatment of estrogen-receptor positive breast cancer in post-menopausal women. Formestane suppresses estrogen production from anabolic steroids or prohormones. Formestane is also a prohormone of 4-hydroxytestosterone, an active steroid with weak androgenic activity and mild aromatase inhibitor activity....
Approved
Investigational
Withdrawn
Matched Description: … With the discovery of newer, non-steroidal and steroidal, aromatase inhibitors which were orally active ... Formestane was the first selective, type I, steroidal aromatase inhibitor used in the treatment of estrogen-receptor ... also a prohormone of 4-hydroxytestosterone, an active steroid with weak androgenic activity and mild aromatase …
Matched Categories: … Aromatase Inhibitors ... Enzyme Inhibitors ... Steroid Synthesis Inhibitors …
Matched Categories: … Aromatase Inhibitors ... Enzyme Inhibitors ... Steroid Synthesis Inhibitors …
Elacestrant
Elacestrant is a non-steroidal small molecule and an estrogen receptor (ER) antagonist.[A256838,L44918] In January 2023, it was approved by the FDA for the treatment of ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer.[L44918,L44948] It received a similar approval in the EU in September 2023. Elacestrant binds to estrogen receptor-alpha (ERα)...
Approved
Investigational
Matched Description: … L44948] Other types of endocrine therapy, such as selective estrogen receptor modulators (SERMs) and aromatase ... inhibitors (AIs), may lead to drug resistance over time; therefore, the use of a SERD represents a therapeutic …
Matched Categories: … BCRP/ABCG2 Inhibitors ... P-glycoprotein inhibitors …
Matched Categories: … BCRP/ABCG2 Inhibitors ... P-glycoprotein inhibitors …
Zucapsaicin
Zucapsaicin, the cis-isomer of capsaicin, is a topical analgesic used to treat osteoarthritis of the knee and other neuropathic pain. It is a modulator of transient receptor potential cation channel subfamily V member 1 (TRPV-1), also known as the vanilloid or capsaicin receptor 1, that reduces pain and improves articular...
Approved
Investigational
Matched Categories: … Cytochrome P-450 CYP1A2 Inhibitors ... Cytochrome P-450 CYP2C19 Inhibitors ... Cytochrome P-450 CYP2C9 Inhibitors ... Cytochrome P-450 CYP2E1 Inhibitors ... Cytochrome P-450 Enzyme Inhibitors …
Aminoglutethimide
An aromatase inhibitor that produces a state of "medical" adrenalectomy by blocking the production of adrenal steroids. It also blocks the conversion of androgens to estrogens. Aminoglutethimide has been used in the treatment of advanced breast and prostate cancer. It was formerly used for its weak anticonvulsant properties. (From Martindale,...
Approved
Investigational
Matched Description: … An aromatase inhibitor that produces a state of "medical" adrenalectomy by blocking the production of …
Matched Categories: … Aromatase Inhibitors ... Enzyme Inhibitors ... Steroid Synthesis Inhibitors …
Matched Categories: … Aromatase Inhibitors ... Enzyme Inhibitors ... Steroid Synthesis Inhibitors …
Phenelzine
Phenelzine, with the formula β-phenylethylhydrazine, is a monoamine oxidase inhibiting antidepressant that is effective in the treatment of panic disorder and social anxiety disorder. It was developed by Parke Davis and originally FDA approved on June 9th, 1961. It is currently approved under prescription by the name of Nardil.
Approved
Matched Categories: … Enzyme Inhibitors ... Monoamine Oxidase Inhibitors ... Cytochrome P-450 CYP2C19 Inhibitors ... Cytochrome P-450 CYP2C8 Inhibitors ... Cytochrome P-450 CYP2D6 Inhibitors …
Omacetaxine mepesuccinate
Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the plant, Cephalotaxus species. In October 2005, omacetaxine mepesuccinate...
Approved
Investigational
Matched Description: … Synribo and FDA approved for patients who are intolerant and/or resistant to two or more tyrosine kinase inhibitors …
Matched Categories: … Enzyme Inhibitors ... Protein Synthesis Inhibitors …
Matched Categories: … Enzyme Inhibitors ... Protein Synthesis Inhibitors …
Tipranavir
Tipranavir is a sulfonamide-containing dyhydropyrone and a nonpeptidic protease inhibitor that targets the HIV protease. Tipranavir and ritonavir are coadministered to treat HIV.
Approved
Investigational
Matched Categories: … Enzyme Inhibitors ... BSEP/ABCB11 Inhibitors ... OATP1B3 inhibitors ... Protease Inhibitors ... HIV Protease Inhibitors …
Moexipril
Moexipril is a non-sulfhydryl containing precursor of the active angiotensin-converting enzyme (ACE) inhibitor moexiprilat. It is used to treat high blood pressure (hypertension). It works by relaxing blood vessels, causing them to widen. Lowering high blood pressure helps prevent strokes, heart attacks and kidney problems.
Approved
Matched Categories: … Enzyme Inhibitors ... Protease Inhibitors ... ACE Inhibitors and Diuretics ... Angiotensin-Converting Enzyme Inhibitors …
Prasugrel
Prasugrel, a thienopyridine derivative, is a platelet activation and aggregation inhibitor structurally and pharmacologically related to clopidogrel and ticlopidine. Similar to clopidogrel, prasugrel is a prodrug that requires enzymatic transformation in the liver to its active metabolite, R-138727. R-138727 irreversibly binds to P2Y12 type ADP receptors on platelets thus preventing...
Approved
Matched Categories: … Platelet Aggregation Inhibitors Excl. Heparin …
Human C1-esterase inhibitor
C1 Esterase Inhibitor (Human) is composed of purified endogenous complement component-1 esterase inhibitor (hC1INH) isolated from human plasma. The primary function of endogenous C1INH is to regulate the activation of the complement and contact system pathways.[L16586, L16606]
This drug is indicated for prophylaxis and treatment of Hereditary Angioedema (HAE), a...
Approved
Matched Categories: … C1 inhibitors ... Enzyme Inhibitors ... Protease Inhibitors ... Kallikrein Inhibitors ... Serine Protease Inhibitors …
Ritonavir
Ritonavir is an HIV protease inhibitor that interferes with the reproductive cycle of HIV. Although it was initially developed as an independent antiviral agent, it has been shown to possess advantageous properties in combination regimens with low-dose ritonavir and other protease inhibitors. It is now more commonly used as a...
Approved
Investigational
Matched Description: … It is now more commonly used as a booster of other protease inhibitors and is available in both liquid ... possess advantageous properties in combination regimens with low-dose ritonavir and other protease inhibitors ... potent CYP3A inhibitor that increases peak and trough plasma drug concentrations of other protease inhibitors …
Matched Categories: … BCRP/ABCG2 Inhibitors ... Enzyme Inhibitors ... BSEP/ABCB11 Inhibitors ... OATP1B3 inhibitors ... Protease Inhibitors …
Matched Categories: … BCRP/ABCG2 Inhibitors ... Enzyme Inhibitors ... BSEP/ABCB11 Inhibitors ... OATP1B3 inhibitors ... Protease Inhibitors …
Ximelagatran
Ximelagatran is an anticoagulant intended to become a replacement for warfarin by overcoming the dietary restrictions, drug interaction, and monitoring issues associated with the former. In 2006, its manufacturer AstraZeneca announced that it would not attempt to market ximelagatran after reports of hepatotoxicity (liver damage) during trials, and to discontinue...
Approved
Investigational
Withdrawn
Matched Categories: … Enzyme Inhibitors ... Protease Inhibitors ... Serine Protease Inhibitors …
Amprenavir
Amprenavir is a protease inhibitor used to treat HIV infection.
Approved
Investigational
Matched Categories: … Enzyme Inhibitors ... Protease Inhibitors ... HIV Protease Inhibitors ... Viral Protease Inhibitors ... OATP1B1/SLCO1B1 Inhibitors …
Nelfinavir
Nelfinavir is a potent HIV-1 protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children. Nelfinavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles.
Approved
Matched Categories: … OCT1 inhibitors ... BCRP/ABCG2 Inhibitors ... Enzyme Inhibitors ... OATP1B3 inhibitors ... Protease Inhibitors …
Pyridostigmine
Myasthenia gravis is an autoimmune disease involving dysfunction at the neuromuscular junction, most commonly due to autoantibodies directed against the acetylcholine receptor (AChR), which results in muscle tone loss, muscle weakness, and fatigue. Acetylcholinesterase inhibitors have been the symptomatic treatment of choice in myasthenia gravis since the 1930s with the...
Approved
Investigational
Matched Description: … [A231004] Acetylcholinesterase inhibitors have been the symptomatic treatment of choice in myasthenia …
Matched Categories: … Enzyme Inhibitors ... Cholinesterase Inhibitors …
Matched Categories: … Enzyme Inhibitors ... Cholinesterase Inhibitors …
Raltegravir
Raltegravir is an antiretroviral drug produced by Merck & Co., used to treat HIV infection. It received approval by the U.S. Food and Drug Administration (FDA) on 12 October 2007, the first of a new class of HIV drugs, the integrase inhibitors, to receive such approval.
Approved
Matched Description: … Drug Administration (FDA) on 12 October 2007, the first of a new class of HIV drugs, the integrase inhibitors …
Matched Categories: … Enzyme Inhibitors ... Integrase Inhibitors ... HIV Integrase Inhibitors …
Matched Categories: … Enzyme Inhibitors ... Integrase Inhibitors ... HIV Integrase Inhibitors …
Belinostat
Belinostat is a novel agent that inhibits the enzyme histone deacetylase (HDAC) with a sulfonamide-hydroxamide structure. It was developed as an orphan drug to target hematological malignancies and solid tumors by TopoTarget. The safety and efficacy of belinostat is currently being evaluated for use in combination with traditional front-line therapies...
Approved
Investigational
Matched Categories: … Enzyme Inhibitors ... Histone Deacetylase Inhibitors ... Cytochrome P-450 CYP2C8 Inhibitors ... Cytochrome P-450 CYP2C9 Inhibitors ... Cytochrome P-450 Enzyme Inhibitors …
Astemizole
Astemizole is a long-acting, non-sedating second generation antihistamine used in the treatment of allergy symptoms. It was withdrawn from market by the manufacturer in 1999 due to the potential to cause arrhythmias at high doses, especially when when taken with CYP inhibitors or grapefruit juice.
Approved
Withdrawn
Matched Description: … 1999 due to the potential to cause arrhythmias at high doses, especially when when taken with CYP inhibitors …
Matched Categories: … P-glycoprotein inhibitors ... Cytochrome P-450 CYP3A Inhibitors ... Cytochrome P-450 CYP3A4 Inhibitors ... Cytochrome P-450 Enzyme Inhibitors ... Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) …
Matched Categories: … P-glycoprotein inhibitors ... Cytochrome P-450 CYP3A Inhibitors ... Cytochrome P-450 CYP3A4 Inhibitors ... Cytochrome P-450 Enzyme Inhibitors ... Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) …
Diclofenamide
A carbonic anhydrase inhibitor that is used in the treatment of glaucoma.
Approved
Investigational
Matched Categories: … Enzyme Inhibitors ... Carbonic Anhydrase Inhibitors …
Donepezil
In 2016, the global burden of dementia was estimated to be 43.8 million, demonstrating a significant increase from a global prevalence of 20.2 million in 1990. Donepezil, also known as Aricept, is a piperidine derivative acetylcholinesterase inhibitor used in the management of the dementia of Alzheimer's Disease, and in some...
Approved
Matched Categories: … Enzyme Inhibitors ... Cholinesterase Inhibitors …
Nefazodone
Nefazodone hydrochloride (trade name Serzone) is an antidepressant drug marketed by Bristol-Myers Squibb. Its sale was discontinued in 2003 in some countries, due to the small possibility of hepatic (liver) injury. Drug-induced hepatic injuries were associated with an risk of elevated need for a liver transplant, or even death, with...
Approved
Withdrawn
Matched Categories: … OATP1B3 inhibitors ... P-glycoprotein inhibitors ... Cytochrome P-450 CYP3A Inhibitors ... Cytochrome P-450 CYP2D6 Inhibitors ... Cytochrome P-450 CYP3A4 Inhibitors …
Rabeprazole
Rabeprazole is an antiulcer drug in the class of proton pump inhibitors. It is a prodrug - in the acid environment of the parietal cells it turns into active sulphenamide form. Rabeprazole inhibits the H+, K+ATPase of the coating gastric cells and dose-dependent oppresses basal and stimulated gastric acid secretion.
Approved
Investigational
Matched Description: … Rabeprazole is an antiulcer drug in the class of proton pump inhibitors. …
Matched Categories: … Enzyme Inhibitors ... BCRP/ABCG2 Inhibitors ... Proton Pump Inhibitors ... Proton-pump Inhibitors ... Cytochrome P-450 CYP1A2 Inhibitors …
Matched Categories: … Enzyme Inhibitors ... BCRP/ABCG2 Inhibitors ... Proton Pump Inhibitors ... Proton-pump Inhibitors ... Cytochrome P-450 CYP1A2 Inhibitors …
Displaying drugs 1 - 25 of 2428 in total